Will be able to manufacture, supply 10 crore Covishield doses in June: Serum Institute to Centre

Serum Institute of India (SII) has informed the government that it will be able to manufacture and supply nine to 10 crore doses of Covishield in June, official sources said on Sunday amid complaint by states about the shortage of anti-coronavirus vaccine jabs. In a recent letter to Union Home Minister Amit Shah, SII said its employees have been working round the clock in spite of various challenges because of the pandemic.

“We are pleased to inform that in the month of June we will be able to manufacture and supply nine to 10 crore doses of our Covishield vaccine to the country as compared to our production capacity of 6.5 crore doses in May,” Prakash Kumar Singh, the Director of Government and Regulatory Affairs at SII, said in the letter.

Singh also thanked Shah for his “valuable guidance and continuous support” at various stages of their endeavour to make India ‘aatmanirbhar’ (self-sufficient) in Covid-19 vaccines and making them available for the people of the country.

“Serum Institute of India has always been sincerely concerned about the protection of the citizens of our country and world at large from Covid-19. Under the leadership of our CEO, Adar C Poonawalla, our team have been working relentlessly shoulder to shoulder with our government to fight the Covid-19 pandemic,” he said in the letter.

“We assure you that with the support of the Government of India and under your kind guidance, we are trying our best by utilizing all of our resources to increase our production capacity of Covishield in the coming month also.”

In early May, SII had communicated to the Centre that production of Covishield would be ramped up to 6.5 crore in June, seven crore in July and 10 crore each in August and September.

India is currently using made-in-India vaccines — Covishield manufactured by SII and Covaxin of Bharat Biotech — in its Covid-19 immunisation programme.

The Russian Sputnik V is the third vaccine to get approval from the Drug Controller General of India (DCGI) for emergency use and is being used in a few private hospitals.

  • Related Posts

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    India’s $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face tariffs of 100% from Aug…

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    New Delhi: A joint operation by the Delhi Police Crime Branch, the Central Drugs Standard Control Organisation (CDSCO) and the Gautam Buddha Nagar District Drug Department uncovered a suspected illegal…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

    Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    CDSCO declares 159 drug samples as NSQs in June

    CDSCO declares 159 drug samples as NSQs in June